Sonova (OTCMKTS:SONVY) versus AxoGen (AXGN) Head to Head Review

Sonova (OTCMKTS: SONVY) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.


How to Become a New Pot Stock Millionaire

This table compares Sonova and AxoGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sonova N/A N/A N/A
AxoGen -17.29% -70.63% -22.33%

Valuation and Earnings

This table compares Sonova and AxoGen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sonova $2.43 billion 4.40 $354.51 million N/A N/A
AxoGen $60.43 million 21.96 -$10.44 million ($0.31) -123.87

Sonova has higher revenue and earnings than AxoGen.

Volatility and Risk

Sonova has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sonova and AxoGen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonova 0 0 0 0 N/A
AxoGen 0 0 8 0 3.00

AxoGen has a consensus target price of $33.14, suggesting a potential downside of 13.69%. Given AxoGen’s higher probable upside, analysts clearly believe AxoGen is more favorable than Sonova.


Sonova pays an annual dividend of $0.27 per share and has a dividend yield of 0.8%. AxoGen does not pay a dividend.

Insider & Institutional Ownership

0.2% of Sonova shares are held by institutional investors. Comparatively, 67.8% of AxoGen shares are held by institutional investors. 7.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Sonova beats AxoGen on 7 of the 12 factors compared between the two stocks.

Sonova Company Profile

Sonova Holding AG designs, develops, manufactures, and distributes hearing systems for adults and children with hearing impairment. It offers hearing instruments, cochlear implants, wireless communication products, and rechargeable hearing aids, as well as professional audiological services. The company provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand name; and professional audiological services under the Connect Hearing brand name. Sonova Holding offers its products through a sales and distribution network, which comprise approximately 50 Sonova-owned wholesale companies and 100 independent distributors; and AudioNova retail network of approximately 3,300 locations in 12 markets. It operates in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

AxoGen Company Profile

AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive News & Ratings for Sonova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonova and related companies with's FREE daily email newsletter.

Leave a Reply